Stelara (ustekinumab) vs Zoryve (roflumilast)
Stelara (ustekinumab) vs Zoryve (roflumilast)
Stelara (ustekinumab) is a biologic medication primarily used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease by targeting interleukins IL-12 and IL-23, which are involved in inflammatory and immune responses. Zoryve (roflumilast) is a topical phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of plaque psoriasis, including in individuals with a body surface area involvement of up to 20%. When deciding between Stelara and Zoryve, one should consider the severity and type of their condition, the method of administration (Stelara is given as an injection, while Zoryve is applied as a cream), and consult with their healthcare provider to assess the most appropriate treatment based on their medical history and individual health needs.
Difference between Stelara and Zoryve
Metric | Stelara (ustekinumab) | Zoryve (roflumilast) |
---|---|---|
Generic name | Ustekinumab | Roflumilast |
Indications | Plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis | Plaque psoriasis |
Mechanism of action | Interleukin-12 and interleukin-23 antagonist | Phosphodiesterase 4 (PDE4) inhibitor |
Brand names | Stelara | Zoryve |
Administrative route | Subcutaneous injection, intravenous infusion | Topical |
Side effects | Nasopharyngitis, upper respiratory tract infection, headache, fatigue | Diarrhea, headache, insomnia, nausea, decreased appetite, back pain |
Contraindications | Active tuberculosis, hypersensitivity to ustekinumab or excipients | Hypersensitivity to roflumilast or any component of the formulation |
Drug class | Monoclonal antibody | Phosphodiesterase 4 (PDE4) inhibitor |
Manufacturer | Janssen Biotech | Arcutis Biotherapeutics |
Efficacy
Efficacy of Stelara (Ustekinumab) for Psoriasis
Stelara (ustekinumab) is a biologic medication approved by the FDA for the treatment of moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy. Ustekinumab works by targeting interleukin-12 and interleukin-23, specific proteins in the immune system that are known to play a key role in the inflammatory processes associated with psoriasis. Clinical trials have demonstrated that Stelara can lead to significant skin clearance in many patients. In these trials, a substantial proportion of patients achieved at least a 75% reduction in the Psoriasis Area and Severity Index (PASI 75) score, which is a measure of the severity and extent of psoriasis.
The efficacy of Stelara has been observed as early as 12 weeks after the initial dose, with continued improvement over time. Long-term studies have shown that the therapeutic effects of Stelara are maintained for several years in many patients, with a good safety profile. The treatment is typically administered as an initial dose followed by a dose four weeks later, and then every 12 weeks thereafter. The convenience of this dosing schedule, combined with the significant improvement in psoriasis symptoms, has made Stelara a valuable treatment option for many patients.
Efficacy of Zoryve (Roflumilast) for Psoriasis
Zoryve (roflumilast) is a phosphodiesterase-4 (PDE4) inhibitor approved by the FDA for the topical treatment of plaque psoriasis, including intertriginous areas, in adults and pediatric patients 12 years of age and older. Roflumilast cream is designed to reduce inflammation by inhibiting the activity of PDE4, an enzyme that contributes to the inflammatory response seen in psoriasis. While Zoryve is a newer treatment option compared to traditional systemic therapies and biologics, clinical trials have shown promising results in reducing the signs and symptoms of plaque psoriasis.
In pivotal clinical trials, Zoryve demonstrated efficacy in achieving clear or almost clear skin as assessed by the Investigator Global Assessment (IGA) score, with a significant number of patients reaching this endpoint compared to placebo. The cream formulation allows for direct application to affected areas, which can be particularly beneficial for patients with localized or difficult-to-treat plaques. As a topical treatment, Zoryve offers an alternative for patients who may prefer to avoid systemic treatments or for whom systemic therapies are not suitable.
Regulatory Agency Approvals
Stelara
Zoryve
Access Stelara or Zoryve today
If Stelara or Zoryve are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us